Twin Tree Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,769
| Closed | -$3.44M | – | 1724 |
|
|
2026
Q1 | $3.47M | Buy |
+7,769
| New | +$3.62M | 0.07% | 309 |
|
|
2025
Q2 | – | Sell |
-8,773
| Closed | -$4.04M | – | 1954 |
|
|
2025
Q1 | $4.25M | Buy |
+8,773
| New | +$4.09M | 0.01% | 949 |
|
|
2024
Q3 | – | Sell |
-11,661
| Closed | -$5.6M | – | 1802 |
|
|
2024
Q2 | $5.47M | Buy |
+11,661
| New | +$5.06M | 0.01% | 736 |
|
|
2024
Q1 | – | Sell |
-129,852
| Closed | -$54.9M | – | 1642 |
|
|
2023
Q4 | $52.8M | Buy |
129,852
+49,532
| +62% | +$18.3M | 0.1% | 191 |
|
|
2023
Q3 | $27.9M | Buy |
80,320
+52,863
| +193% | +$18.5M | 0.06% | 274 |
|
|
2023
Q2 | $9.66M | Buy |
+27,457
| New | +$9.25M | 0.01% | 624 |
|
|
2023
Q1 | – | Sell |
-11,540
| Closed | -$3.33M | – | 1612 |
|
|
2022
Q4 | $3.33M | Sell |
11,540
-17,654
| -60% | -$5.38M | 0.01% | 829 |
|
|
2022
Q3 | $8.45M | Buy |
29,194
+27,366
| +1,497% | +$7.87M | 0.02% | 608 |
|
|
2022
Q2 | $515K | Sell |
1,828
-134,763
| -99% | -$36.1M | ﹤0.01% | 1288 |
|
|
2022
Q1 | $35.6M | Sell |
136,591
-4,228
| -3% | -$1M | 0.06% | 292 |
|
|
2021
Q4 | $30.9M | Buy |
140,819
+122,616
| +674% | +$23.8M | 0.06% | 285 |
|
|
2021
Q3 | $3.3M | Buy |
18,203
+7,344
| +68% | +$1.43M | 0.01% | 908 |
|
|
2021
Q2 | $2.19M | Sell |
10,859
-32,408
| -75% | -$6.78M | 0.01% | 871 |
|
|
2021
Q1 | $9.3M | Buy |
43,267
+43,203
| +67,505% | +$9.49M | 0.03% | 473 |
|
|
2020
Q4 | $15K | Buy |
+64
| New | +$14.7K | ﹤0.01% | 1216 |
|
|
2020
Q3 | – | Sell |
-17,608
| Closed | -$4.86M | – | 1612 |
|
|
2020
Q2 | $5.11M | Buy |
17,608
+6,398
| +57% | +$1.73M | 0.02% | 649 |
|
|
2020
Q1 | $2.67M | Sell |
11,210
-23,410
| -68% | -$5.37M | 0.01% | 645 |
|
|
2019
Q4 | $7.58M | Buy |
34,620
+28,311
| +449% | +$5.73M | 0.03% | 413 |
|
|
2019
Q3 | $1.07M | Sell |
6,309
-2,542
| -29% | -$450K | ﹤0.01% | 819 |
|
|
2019
Q2 | $1.62M | Sell |
8,851
-5,953
| -40% | -$1.04M | 0.01% | 705 |
|
|
2019
Q1 | $2.72M | Buy |
+14,804
| New | +$2.73M | 0.01% | 589 |
|
|
2018
Q4 | – | Sell |
-36,049
| Closed | -$6.95M | – | 1527 |
|
|
2018
Q3 | $6.95M | Buy |
36,049
+18,440
| +105% | +$3.28M | 0.05% | 321 |
|
|
2018
Q2 | $2.99M | Buy |
17,609
+16,505
| +1,495% | +$2.56M | 0.02% | 546 |
|
|
2018
Q1 | $180K | Sell |
1,104
-49,050
| -98% | -$8.01M | ﹤0.01% | 925 |
|
|
2017
Q4 | $7.52M | Buy |
50,154
+322
| +0.6% | +$47.7K | 0.06% | 300 |
|
|
2017
Q3 | $7.58M | Buy |
+49,832
| New | +$7.5M | 0.06% | 288 |
|
Other funds holding VRTX
Twin Tree Management's VRTX Position: Q2 2026 in Review
Twin Tree Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 7,769 shares — an estimated $3.44M sold.
Twin Tree Management first reported a position in VRTX in Q3 2017 and held it in 26 quarters. The position peaked at $52.8M in Q4 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Twin Tree Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Twin Tree Management sold 7,769 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.44M.
- Twin Tree Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 26 quarters.
- Twin Tree Management's Vertex Pharmaceuticals position peaked at $52.8M in Q4 2023.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Twin Tree Management's 13F filing for Q2 2026, filed 12 Aug 2026.